Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Sep 28

PMID 34576069

Citations 18

Authors

Anton L Martinez

Jose Brea

Sara Rico

Maria Teresa de Los Frailes

Maria Isabel Loza

Affiliations

Soon will be listed here.

Abstract

Schizophrenia is a major mental illness characterized by positive and negative symptoms, and by cognitive deficit. Although cognitive impairment is disabling for patients, it has been largely neglected in the treatment of schizophrenia. There are several reasons for this lack of treatments for cognitive deficit, but the complexity of its etiology-in which neuroanatomic, biochemical and genetic factors concur-has contributed to the lack of effective treatments. In the last few years, there have been several attempts to develop novel drugs for the treatment of cognitive impairment in schizophrenia. Despite these efforts, little progress has been made. The latest findings point to the importance of developing personalized treatments for schizophrenia which enhance neuroplasticity, and of combining pharmacological treatments with non-pharmacological measures.

Citing Articles

Pharmacological reduction of reverse-translated hippocampal hyperactivity in mouse: relevance for psychosis.

Dybowski F, Scott D, Tamminga C Neuropsychopharmacology. 2025; .

PMID: 40016366 DOI: 10.1038/s41386-025-02077-4.

Exploring Cognitive Deficits and Neuromodulation in Schizophrenia: A Narrative Review.

Hung C, Lin K, Chang H Medicina (Kaunas). 2025; 60(12.

PMID: 39768939 PMC: 11676924. DOI: 10.3390/medicina60122060.

Treating Cognition in Schizophrenia: A Whole Lifespan Perspective.

Penades R, Forte M, Mezquida G, Andres C, Catalan R, Segura B Healthcare (Basel). 2024; 12(21).

PMID: 39517406 PMC: 11545462. DOI: 10.3390/healthcare12212196.

Dynamic stress- and inflammatory-based regulation of psychiatric risk loci in human neurons.

Retallick-Townsley K, Lee S, Cartwright S, Cohen S, Sen A, Jia M bioRxiv. 2024; .

PMID: 39026810 PMC: 11257632. DOI: 10.1101/2024.07.09.602755.

PDE4 inhibitors: potential protective effects in inflammation and vascular diseases.

Fan T, Wang W, Wang Y, Zeng M, Liu Y, Zhu S Front Pharmacol. 2024; 15:1407871.

PMID: 38915460 PMC: 11194378. DOI: 10.3389/fphar.2024.1407871.

References

Weickert T, Weinberg D, Lenroot R, Catts S, Wells R, Vercammen A . Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry. 2015; 20(6):685-94. PMC: 4444978. DOI: 10.1038/mp.2015.11. View

Tropea D, Hardingham N, Millar K, Fox K . Mechanisms underlying the role of DISC1 in synaptic plasticity. J Physiol. 2018; 596(14):2747-2771. PMC: 6046077. DOI: 10.1113/JP274330. View

Pinheiro A, Keefe R, Skelly T, Olarte M, Leviel K, Lange L . AKT1 and neurocognition in schizophrenia. Aust N Z J Psychiatry. 2007; 41(2):169-77. DOI: 10.1080/00048670601109956. View

Lobo R . Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2016; 13(4):220-231. DOI: 10.1038/nrendo.2016.164. View

Dawson N, Thompson R, McVie A, Thomson D, Morris B, Pratt J . Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity. Schizophr Bull. 2010; 38(3):457-74. PMC: 3329989. DOI: 10.1093/schbul/sbq090. View

Clifton N, Morisot N, Girardon S, Millan M, Loiseau F . Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine. Psychopharmacology (Berl). 2012; 225(3):579-94. DOI: 10.1007/s00213-012-2845-3. View

Mondelli V, Cattaneo A, Belvederi Murri M, Di Forti M, Handley R, Hepgul N . Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry. 2011; 72(12):1677-1684. PMC: 4082665. DOI: 10.4088/JCP.10m06745. View

Terry Jr A, Plagenhoef M, Callahan P . Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys. Psychopharmacology (Berl). 2015; 233(5):761-71. PMC: 4752862. DOI: 10.1007/s00213-015-4154-0. View

Montalvo I, Gutierrez-Zotes A, Creus M, Monseny R, Ortega L, Franch J . Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis. PLoS One. 2014; 9(2):e89428. PMC: 3933530. DOI: 10.1371/journal.pone.0089428. View

10.

Huang M, Kwon S, Oyamada Y, Rajagopal L, Miyauchi M, Meltzer H . Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. Pharmacol Biochem Behav. 2015; 138:49-57. DOI: 10.1016/j.pbb.2015.09.011. View

11.

Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B . Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014; 153(1-3):169-76. DOI: 10.1016/j.schres.2014.01.011. View

12.

Koola M . Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia. Mol Neuropsychiatry. 2019; 4(3):134-148. PMC: 6323397. DOI: 10.1159/000494495. View

13.

Goff D, Leahy L, Berman I, Posever T, Herz L, Leon A . A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol. 2001; 21(5):484-7. DOI: 10.1097/00004714-200110000-00005. View

14.

Yao S, Song J, Gao J, Lin P, Yang M, Zahid K . Cognitive Function and Serum Hormone Levels Are Associated with Gray Matter Volume Decline in Female Patients with Prolactinomas. Front Neurol. 2018; 8:742. PMC: 5797301. DOI: 10.3389/fneur.2017.00742. View

15.

Whittington M, Cunningham M, LeBeau F, Racca C, Traub R . Multiple origins of the cortical γ rhythm. Dev Neurobiol. 2010; 71(1):92-106. DOI: 10.1002/dneu.20814. View

16.

Enomoto T, Tatara A, Goda M, Nishizato Y, Nishigori K, Kitamura A . A Novel Phosphodiesterase 1 Inhibitor DSR-141562 Exhibits Efficacies in Animal Models for Positive, Negative, and Cognitive Symptoms Associated with Schizophrenia. J Pharmacol Exp Ther. 2019; 371(3):692-702. DOI: 10.1124/jpet.119.260869. View

17.

Huang M, Felix A, Flood D, Bhuvaneswaran C, Hilt D, Koenig G . The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology (Berl). 2014; 231(23):4541-51. DOI: 10.1007/s00213-014-3596-0. View

18.

Mueser K, McGurk S . Schizophrenia. Lancet. 2004; 363(9426):2063-72. DOI: 10.1016/S0140-6736(04)16458-1. View

19.

Zheng W, Cai D, Zhang Q, He J, Zhong L, Sim K . Adjunctive ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2019; 113:27-33. DOI: 10.1016/j.jpsychires.2019.02.024. View

20.

Ibi D, de la Fuente Revenga M, Kezunovic N, Muguruza C, Saunders J, Gaitonde S . Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects. Nat Neurosci. 2017; 20(9):1247-1259. PMC: 5675106. DOI: 10.1038/nn.4616. View